November 20, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
|
Attention:
|
Tamika N. Sheppard
|
|
|
Re:
|
|
Gyre Therapeutics, Inc.
|
|
|
|
Registration Statement on Form S-3 (File No. 333-283237)
|
Ladies and Gentlemen:
Gyre Therapeutics, Inc. hereby respectfully requests that, pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, the effectiveness of the above-referenced
Registration Statement on Form S‑3 be accelerated so that it will become effective on November 22, 2024, at 4:15 p.m., Eastern Time, or as soon as practicable thereafter, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request
by telephone that such Registration Statement be declared effective at some other time.
We request that we be notified of such effectiveness by a telephone call to Branden C. Berns of Gibson, Dunn & Crutcher at (415) 393-4631.
|
Sincerely,
|
|||
|
GYRE THERAPEUTICS, INC.
|
|||
|
By:
|
|
/s/ Han Ying
|
|
|
|
Han Ying, Ph.D.
|
||
|
|
Chief Executive Officer
|
||
|
cc:
|
Ruoyu Chen, Gyre Therapeutics, Inc.
Ryan A. Murr, Gibson, Dunn & Crutcher LLP
Branden C. Berns, Gibson, Dunn & Crutcher LLP
|